Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Sell

C

Reneo Pharmaceuticals, Inc. Common Stock (RPHM)

Pharmaceutical Preparations

https://www.reneopharma.com

Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.

18575 JAMBOREE ROAD, SUITE 275-S
IRVINE, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/09/2021

Market Cap

51,814,640

Shares Outstanding

33,310,000

Weighted SO

33,311,787

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

PRME --.--%

DNA --.--%

OCEA --.--%

RPRX --.--%

IMMX --.--%

CNSP --.--%

HEPA --.--%

FRLN --.--%

AVRO --.--%

Beta

0.2010

Last Div

0.0000

Range

0.98-9.21

Chg

-0.0100

Avg Vol

134725

Mkt Cap

51814640

Exch

NASDAQ

Country

US

Phone

619 733 3852

DCF Diff

0.6810

DCF

0.8690

Div Yield

0.0000

P/S

70.5922

EV Multiple

-0.2654

P/FV

0.6739

Div Yield %

0.0000

P/E

-0.9163

PEG

0.0389

Payout

0.0000

Current Ratio

57.8561

Quick Ratio

57.8561

Cash Ratio

26.6840

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

203.1304

CCC

-203.1304

Gross Margin

0.8433

Op Margin

-85.6730

Pretax Margin

-77.0259

Net Margin

-77.0259

Eff Tax Rate

-0.0175

ROA

-0.7182

ROE

-0.6253

ROCE

-0.8128

NI/EBT

1.0000

EBT/EBIT

0.8991

EBIT/Rev

-85.6730

Debt Ratio

0.0105

D/E

0.0107

LT Debt/Cap

0.0064

Total Debt/Cap

0.0106

Int Coverage

-61.8937

CF/Debt

-80.6087

Equity Multi

1.0240

Rec Turnover

0.0000

Pay Turnover

1.7969

Inv Turnover

0.0000

FA Turnover

1.2787

Asset Turnover

0.0093

OCF/Share

-1.9850

FCF/Share

-1.9864

Cash/Share

2.2942

OCF/Sales

-90.3828

FCF/OCF

1.0007

CF Coverage

-80.6087

ST Coverage

-200.4260

CapEx Coverage

-1442.1957

Div&CapEx Cov

-1442.1957

P/BV

0.6739

P/B

0.6739

P/S

70.5922

P/E

-0.9163

P/FCF

-0.7805

P/OCF

-0.7808

P/CF

-0.7808

PEG

0.0389

P/S

70.5922

EV Multiple

-0.2654

P/FV

0.6739

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Oct 04, 20:57 OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million Benzinga Oct 03, 00:20 Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure GlobeNewswire Inc. Oct 03, 00:20 Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure GlobeNewswire Inc. Nov 13, 07:35 Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results GlobeNewswire Inc. Nov 02, 07:50 Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire Inc. Oct 25, 07:50 Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings

Revenue Product Segmentation